Amicogen, Inc. (092040.KQ)
KRW 3930.0
(-3.2%)
KRW 3930.0
(-3.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.05 Billion KRW | 73.4% |
| 2022 | -4.92 Billion KRW | -6.45% |
| 2021 | -4.62 Billion KRW | -295.86% |
| 2020 | 2.36 Billion KRW | 190.68% |
| 2019 | -2.6 Billion KRW | -217.09% |
| 2018 | 2.22 Billion KRW | 17.39% |
| 2017 | 1.89 Billion KRW | -54.63% |
| 2016 | 4.17 Billion KRW | 78.74% |
| 2015 | 2.33 Billion KRW | -75.22% |
| 2014 | 9.43 Billion KRW | 7.29% |
| 2013 | 8.79 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.91 Billion KRW | 35.37% |
| 2024 Q1 | -2.95 Billion KRW | 9.9% |
| 2023 FY | -1.31 Billion KRW | 73.4% |
| 2023 Q3 | 1.3 Billion KRW | -7.05% |
| 2023 Q1 | -728.31 Million KRW | 13.21% |
| 2023 Q4 | -3.28 Billion KRW | -352.29% |
| 2023 Q2 | 1.4 Billion KRW | 292.34% |
| 2022 Q4 | -839.15 Million KRW | -1315.3% |
| 2022 FY | -4.92 Billion KRW | -6.45% |
| 2022 Q3 | 69.04 Million KRW | 103.89% |
| 2022 Q2 | -1.77 Billion KRW | 25.4% |
| 2022 Q1 | -2.38 Billion KRW | 3.57% |
| 2021 FY | -4.62 Billion KRW | -295.86% |
| 2021 Q4 | -2.46 Billion KRW | 18.33% |
| 2021 Q2 | 83.84 Million KRW | -89.24% |
| 2021 Q1 | 779.27 Million KRW | 1493.56% |
| 2021 Q3 | -3.02 Billion KRW | -3704.75% |
| 2020 FY | 2.36 Billion KRW | 190.68% |
| 2020 Q1 | -365.1 Million KRW | -138.21% |
| 2020 Q2 | 1.91 Billion KRW | 623.94% |
| 2020 Q3 | 1.15 Billion KRW | -39.73% |
| 2020 Q4 | -55.91 Million KRW | -104.85% |
| 2019 Q3 | -1.6 Billion KRW | 15.54% |
| 2019 Q1 | -49.91 Million KRW | 95.98% |
| 2019 FY | -2.6 Billion KRW | -217.09% |
| 2019 Q4 | 955.62 Million KRW | 159.69% |
| 2019 Q2 | -1.89 Billion KRW | -3697.67% |
| 2018 Q2 | 765.56 Million KRW | -54.66% |
| 2018 FY | 2.22 Billion KRW | 17.39% |
| 2018 Q4 | -1.24 Billion KRW | -222.59% |
| 2018 Q3 | 1.01 Billion KRW | 32.32% |
| 2018 Q1 | 1.68 Billion KRW | -15.31% |
| 2017 FY | 1.89 Billion KRW | -54.63% |
| 2017 Q1 | 635.75 Million KRW | -79.14% |
| 2017 Q2 | 458.27 Million KRW | -27.92% |
| 2017 Q3 | -1.19 Billion KRW | -360.15% |
| 2017 Q4 | 1.99 Billion KRW | 267.23% |
| 2016 FY | 4.17 Billion KRW | 78.74% |
| 2016 Q4 | 3.04 Billion KRW | 287.53% |
| 2016 Q3 | -1.62 Billion KRW | -3492.77% |
| 2016 Q2 | -45.23 Million KRW | -101.62% |
| 2016 Q1 | 2.8 Billion KRW | 21.56% |
| 2015 Q3 | -1.55 Billion KRW | -253.99% |
| 2015 Q2 | 1.01 Billion KRW | 74.49% |
| 2015 Q1 | 580.23 Million KRW | -88.48% |
| 2015 FY | 2.33 Billion KRW | -75.22% |
| 2015 Q4 | 2.3 Billion KRW | 247.77% |
| 2014 Q2 | 1.33 Billion KRW | -26.86% |
| 2014 Q1 | 1.82 Billion KRW | -41.11% |
| 2014 Q3 | 1.23 Billion KRW | -7.9% |
| 2014 Q4 | 5.03 Billion KRW | 309.2% |
| 2014 FY | 9.43 Billion KRW | 7.29% |
| 2013 Q4 | 3.1 Billion KRW | 352.38% |
| 2013 FY | 8.79 Billion KRW | 0.0% |
| 2013 Q2 | 2.77 Billion KRW | 25.02% |
| 2013 Q3 | 685.98 Million KRW | -75.32% |
| 2013 Q1 | 2.22 Billion KRW | 0.0% |
| 2012 Q3 | 968.36 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 101.645% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | 162.593% |
| BINEX Co., Ltd. | 1.04 Billion KRW | -97.277% |
| Bioneer Corporation | 791.75 Million KRW | -159.695% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | 140.524% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 108.182% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 106.651% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 105.834% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | 121.815% |
| Medy-Tox Inc. | 17.32 Billion KRW | 88.13% |
| Peptron, Inc. | -15.6 Billion KRW | 113.178% |
| Genexine, Inc. | -41.24 Billion KRW | 104.986% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | 123.633% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 102.544% |
| ALTEOGEN Inc. | -9.73 Billion KRW | 121.117% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 97.961% |
| SillaJen, Inc. | -21.34 Billion KRW | 109.633% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 21.928% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 111.307% |
| Genomictree Inc. | -17.3 Billion KRW | 111.883% |
| MedPacto, Inc. | -28.75 Billion KRW | 107.151% |
| D&D Pharmatech | -13.48 Billion KRW | 115.246% |
| EASY BIO,Inc. | 20.63 Billion KRW | 90.034% |
| GI Innovation, Inc. | -55.6 Billion KRW | 103.698% |